Back to News
Market Impact: 0.2
Where Will Neurocrine Biosciences Be in 5 Years?
Source: fool.com
Healthcare & BiotechCorporate EarningsCompany FundamentalsCorporate Guidance & Outlook
Ingrezza remains Neurocrine's largest revenue driver, with sales growing 15%. Two late-stage drug candidates face important clinical milestones in 2027, adding pipeline catalysts alongside the current product's growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
NBIX0.35
More News
- SpaceX closes $40 billion debt deal for AI chips, Elon Musk says
- Earnings playbook: Alphabet, Microsoft, Amazon and more report this week. Here's what to expect
- Here are 4 big things we're watching in the stock market this week
- More pain may be coming for the AI trade. Why I’m not giving up on it
- AI Spending Fears Threaten to Swamp Big Tech’s Strong Earnings
- Apple to Unveil Touch-Screen MacBook Pro; Executive Promotions; In-Box Checker